Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma	Relapsed Classic Hodgkin Lymphoma	Recruiting	Phase 2	2026-09-22		NCT04561206

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
City of Hope Medical Center	347
National Cancer Institute (NCI)	3015

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope Medical Center	Duarte	United States	313
Dana-Farber Cancer Institute	Boston	United States	626
Hackensack University Medical Center/John Theurer Cancer Center	Hackensack	United States	1
Sarah Cannon Research Institute	Nashville	United States	119
University of Chicago Cancer Research Center	Chicago	United States	1